These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 22463794)

  • 1. Biomarkers, subgroup evaluation, and clinical trial design.
    Baker SG; Kramer BS; Sargent DJ; Bonetti M
    Discov Med; 2012 Mar; 13(70):187-92. PubMed ID: 22463794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.
    Jiang W; Freidlin B; Simon R
    J Natl Cancer Inst; 2007 Jul; 99(13):1036-43. PubMed ID: 17596577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints.
    Lassere MN
    Stat Methods Med Res; 2008 Jun; 17(3):303-40. PubMed ID: 17925313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients.
    Freidlin B; Simon R
    Clin Cancer Res; 2005 Nov; 11(21):7872-8. PubMed ID: 16278411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating surrogate markers.
    Hughes MD; DeGruttola V; Welles SL
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S1-8. PubMed ID: 7552506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive methods: telling "the rest of the story".
    Emerson SS; Fleming TR
    J Biopharm Stat; 2010 Nov; 20(6):1150-65. PubMed ID: 21058111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset.
    Wang SJ; O'Neill RT; Hung HM
    Pharm Stat; 2007; 6(3):227-44. PubMed ID: 17688238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trial simulation to assist in COPD trial planning and design with a biomarker-based diagnostic: when to pull the trigger?
    Gold DL; Dawson M; Yang H; Parker J; Gossage DL
    COPD; 2014 Apr; 11(2):226-35. PubMed ID: 24111823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cross-validated adaptive signature design.
    Freidlin B; Jiang W; Simon R
    Clin Cancer Res; 2010 Jan; 16(2):691-8. PubMed ID: 20068112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program.
    Wang SJ; Hung HM; O'Neill R
    J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A two-stage Bayesian design for co-development of new drugs and companion diagnostics.
    Karuri SW; Simon R
    Stat Med; 2012 May; 31(10):901-14. PubMed ID: 22238151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for a non-inferiority clinical trial design focused on subpopulations.
    Kulkarni PM; Meadows ES; Ahuja S; Muram D; Plouffe L
    Curr Med Res Opin; 2004 Oct; 20(10):1641-7. PubMed ID: 15462697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omics-based clinical trial designs.
    Buyse M; Michiels S
    Curr Opin Oncol; 2013 May; 25(3):289-95. PubMed ID: 23475192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Key factors in evaluating potential clinical biomarkers.
    Spain M; McDade R
    IDrugs; 2007 Sep; 10(9):633-5. PubMed ID: 17786846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk biomarkers and current strategies for cancer chemoprevention.
    Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
    J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive randomized phase II design for biomarker threshold selection and independent evaluation.
    Renfro LA; Coughlin CM; Grothey AM; Sargent DJ
    Chin Clin Oncol; 2014 Mar; 3(1):3. PubMed ID: 25842081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating biomarkers in clinical trials.
    Buyse M; Michiels S; Sargent DJ; Grothey A; Matheson A; de Gramont A
    Expert Rev Mol Diagn; 2011 Mar; 11(2):171-82. PubMed ID: 21405968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers and surrogates in clinical studies.
    Rigatto C; Barrett BJ
    Methods Mol Biol; 2009; 473():137-54. PubMed ID: 19160736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.
    Lal P; Su Z; Holweg CT; Silverman GJ; Schwartzman S; Kelman A; Read S; Spaniolo G; Monroe JG; Behrens TW; Townsend MJ
    Arthritis Rheum; 2011 Dec; 63(12):3681-91. PubMed ID: 22127691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.